Fill in your details on the right-hand side to view our 2024 brochure and discover the wealth of opportunities available to you, to enable you to tackle key industry challenges and forge the right partnerships to grow your business.
“WHIS has established itself as the leading conference in this field, bringing together startups,
corporates and investors. If you are interested in the future of Women’s Health, look no further.”
Chandra Leo, Parter, HBM Partners
![](https://www.kisacoresearch.com/sites/default/files/styles/panopoly_image_quarter/public/day_1_338_0.jpeg?itok=MqvJLC2g&c=8644a003af9ededf6cb57efeada70f7b)
![](https://www.kisacoresearch.com/sites/default/files/styles/panopoly_image_quarter/public/day_1_049_0.jpeg?itok=u8ExDqoE&c=8644a003af9ededf6cb57efeada70f7b)
Take a sneak peek at the agenda to get a glimpse of what's in store for you:
State of Play in Europe: Should the EU Adopt a Centralised Strategy in Women’s Health?
This opening discussion takes a bird’s eye look at the landscape, examining whether a centralised approach
towards women’s health will play a pivotal role in overcoming the fragmentation of EU healthcare &
reimbursement to accelerate innovation & investment and improve outcomes. Hear from industry experts as
they discuss the impact of the 2024 European Parliamentary Elections, and the European Institute of Women’s
Health’s EU Manifesto for Women’s Health in driving policy changes and consider the impact that the EU4Health
Programme has in championing EU Financial support of healthcare. Taking a comparative approach, panellists
will assess what the Women’s Health Strategy for England has contributed towards innovation and research, and
whether it is a replicable model for the EU.
Beatrice Lemberg, Senior Director of Marketing, Hologic
Accelerating Women’s Health through Early-Stage Clinical & Academic Research Partnerships
As the Biotech hub of the world, Europe is fertile ground for disruptive research set to transform women’s
health innovation. But how do we champion early-stage clinical development and research and better
translate it into outcomes? How can research and development be better incubated and accelerated?
What strategies should be adopted to ensure that life science innovation and therapeutic solutions are
being prioritized? What are large pharmaceutical companies looking for, and what are some examples
partnerships in the space? Join this opening discussion to unpack these questions, and hearing from
examples of partnerships responsible for leading the way.
Marco Rüedi, Mentor, Tech4Eva, Senior Business Coach,EPFL Innovation Park
Trine Bartholdy, Chief Innovation Officer, BioInnovation Institute
Jump to:
Day 1
| Day 2